(D) Longitudinal measurements of metastasis rates among all breast cancer patients (n = 211), patients with ≥2% CD44+/CD24- cells (n = 68) and the C1 group of patients with <2% of CD44+/CD24- and ≥19.5% CD44-/CD24- cells (n = 153). Here, CD24 is linked to breast cancer.